Trial Profile
A Phase II Study of Pazopanib to Enable Partial Nephrectomy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jan 2016 Status changed from suspended to completed as reported in the ClinicalTrials.gov record.
- 11 Nov 2014 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
- 18 Jul 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Jan 2015 as per ClinicalTrials.gov record.